On the substative issue of the Pharm. outlicence I must admit I am a little confused.
Would the SPPI/GPCB contract call for a share of the retail level revenue? In which case SPPI was uneffected and I don't even know why they whent to arbitration.
If the contract calls for just a percentage of GPCB's revenue, then I would think they had a clear case (unless they totally f'd up on the contract).
Any clues here, Due?
I agree the rest of the issues were always stupid.
BTW, If this is good for GPCB, will the GTCB pps go up?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.